Helping Founders Realize Their Vision
Your founder-friendly growth capital source.
- Maximizing value for founders and investors.
- Providing customized capital solutions ranging from $2MM to $20MM+.
- Serving innovative companies with exceptional, scalable business models.
OUR FOCUS
Innovative Companies
$3MM+ in Annual Recurring Revenue
or
$1.5MM+ in EBITDA
Providing
$2MM to $20MM+ in growth capital
- $150MM+ credit provided to help portfolio companies scale
- Access to co-investors with $1.5B+ assets under management
- $750MM+ incremental exit value for founders and investors
Great relationships start with listening and understanding.
Vision
Business Model
Market
Milestones
Capital Needs
Future








This financing will play a pivotal role in the upcoming launch of our dog and cat food product line, an initiative we’re incredibly passionate about. With every product purchased, we’ll donate a meal to an animal in need, creating a meaningful way for consumers to make a direct impact. This is more than a product launch—it’s a commitment to feeding and saving more animals together with our growing community.” –John Hussey, CEO of CUDDLY



Working with RevTek Capital
RevTek Capital was founded in 2021 by a group of entrepreneurs and banking experts who believed there was a better way to fund growing companies. Our funding is structured so we win when you win. Our return depends on your company’s performance, meaning it’s in our best interest to work with you to help you grow. We can be involved as much or as little as you like. Together with our community of entrepreneurs and experts, we help as needed.
We succeed when you succeed.
Recent Articles more...

The New Playbook for SaaS Growth: Smart Marketing, Strong Funding
In 2025, scaling a SaaS business requires more than just a great product. RevTek Capital’s latest guide outlines a comprehensive growth strategy combining smart

Newsletter – April 2025
In RevTek Capital’s April 2025 newsletter, discover how spring is fueling strategic SaaS growth. Learn how Apex Biologix is transforming regenerative medicine through a

Apex Biologix Closes a Strategic Financing Round with RevTek Capital
Apex Biologix, a pioneer in regenerative medicine, has closed a strategic financing round with RevTek Capital to support its rapid growth and expand its

Newsletter – Mar 2025
In our March 2025 newsletter, we delve into current market trends, share expert investment strategies, and provide updates on our ongoing projects. Stay informed
Popular Articles more...

The New Playbook for SaaS Growth: Smart Marketing, Strong Funding
In 2025, scaling a SaaS business requires more than just a great product. RevTek Capital’s latest guide outlines a comprehensive growth strategy combining smart

Newsletter – April 2025
In RevTek Capital’s April 2025 newsletter, discover how spring is fueling strategic SaaS growth. Learn how Apex Biologix is transforming regenerative medicine through a

Apex Biologix Closes a Strategic Financing Round with RevTek Capital
Apex Biologix, a pioneer in regenerative medicine, has closed a strategic financing round with RevTek Capital to support its rapid growth and expand its

Newsletter – Mar 2025
In our March 2025 newsletter, we delve into current market trends, share expert investment strategies, and provide updates on our ongoing projects. Stay informed